SavedAdd your journal

Journals / Anadolu Tıp Dergisi / 2002 / Cilt: 4 - Sayı: 1

Fulminant hepatic failure as a result of toxicity of anti-tuberculous drugs: Report of two cases

Antitüberküloz ilaçların toksisitesine bağlı fulminan karaciğer yetersizliği: İki olgu sunumu

Fikret DEMİRCİ
Mehmet KORUK
M. Cemil SAVAŞ
Abdurrahman KADAYIFÇI
Pages
51–54
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was focused on the points that physicians should be careful concerning about the hepatotoxicity of the drugs in the management of patients during antituberculous therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hepatic toxic effects of drugs may result in serious conditions and death.
📊
Key Findings & Data:The fulminant hepatit series as a result of antituberculous therapy are frequently reported in recent years.
💡
Conclusion & Impact:It was focused on the points that physicians should be careful concerning about the hepatotoxicity of the drugs in the management of patients during antituberculous therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hepatic toxic effects of drugs may result in serious conditions and death. The fulminant hepatit series as a result of antituberculous therapy are frequently reported in recent years. The present study reported two cases diagnosed as fulminant hepatitis as a result of antituberculous drugs (isoniazid, rifampicin and pyrazinamide). The patients have been lost in spite of aggresive supportive treatment. It was focused on the points that physicians should be careful concerning about the hepatotoxicity of the drugs in the management of patients during antituberculous therapy.

Özet

İlaçların karaciğer toksisiteleri önemli sonuçlara ve ölüme yol açabilir. Antitüberküloz tedaviye bağlı fulminan hepatit serileri son yıllarda çok daha sıklıkla yayınlanmaktadır. Bu çalışmada Gaziantep Üniversitesi Tıp fakültesi, gastroenteroloji bilim dalında antitüberküloz ilaçlara (isoniazid, rifampisin ve pirazinamid) bağlı fulminan karaciğer yetmezliği tanısı konulan ve eksitus olan iki olgu sunulmuştur. Olgular literatür ışığında tartışılarak antitüberküloz tedavi esnasında özellikle hepatotoksisite yönünden hasta takibinde dikkat edilmesi gereken noktalar vurgulanmıştır.

🔖

Cite This Article

DEMİRCİ, F., KORUK, M., SAVAŞ, M. C., KADAYIFÇI, A. (2022). Fulminant hepatic failure as a result of toxicity of anti-tuberculous drugs: Report of two cases. Anadolu Tıp Dergisi, Cilt: 4 - Sayı: 1, 51–54. https://ajindex.com/articles/438151

References (13)

  1. Acharya SK, Dasarathy S, Kumer L, et al. Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology 1996; 23: 1448-55
  2. Bernuau J, Benhamou JP. Fulminant and subfulmiruint liver failure, Jn: Bircher J, ed. Oxford Textbook of Clinical Hepatology. Second edition, Vol 2. Oxford: Oxford University Press, 1999; 1341-72
  3. Bernuau J, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1992; 339: 952-5
  4. Caplin M, Thompson N, Hamilton M, et al. Antituberculous therapy and acute liver failure. Lancet 1995:345:1171
  5. Durand F, Bemuau J, Pessayre D, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995; 21:929-32
  6. Durand F, Pessayre D, Fournier M, et al. Anütıberculous therapy and acute liver failure. Lancet 1995;345:1170
  7. Farrell GC. Drug-induced acule hepatitis.İn:Drung-induced liver disease, Farrell GC, ed. Edinburg: Churcill Livingstone, 1994: 247-99
  8. Girotto L, Gjonovich A, Preciso G. Fulminant liver failure caused by antituberculous drugs. Report of a clinical case. Minerva Anestesiol 2000; 66(4): 249-51
  9. Langley PG, Hughes RD, Williams R. Increased factor VIII complex in fulminant hepatic failure. Thrombosis and Haemostasis 1985; 54: 693-6
  10. Mc Keon J, Patel AM. Antituberculous therapy and acute liver failure. Lancet 1995 May 6; 345: 1170
  11. Moitinho E, Saimeron JM, Mas A, et al. Severe hepatotoxicity of luberculostatic agents. Increase in the incidence. Gastroenterol Hepatoi 1996; 19(9): 448-51
  12. Moulding TS, Redecker AG, Kane] GC. Twenty isoniazid-associated deaths in one state. Am Rev Resp Dis 1989; 140: 700-5
  13. Singh J, Garg PK, Tandan RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastraenterol 1996;22(3):211-4.